Based on the Integra LifeSciences Holdings stock forecast from 6 analysts, the average analyst target price for Integra LifeSciences Holdings is USD 24.50 over the next 12 months. Integra LifeSciences Holdings’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Integra LifeSciences Holdings is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Integra LifeSciences Holdings’s stock price was USD 22.88. Integra LifeSciences Holdings’s stock price has changed by -7.67% over the past week, +15.56% over the past month and -41.45% over the last year.
No recent analyst target price found for Integra LifeSciences Holdings
No recent average analyst rating found for Integra LifeSciences Holdings
Company Overview Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Read Less
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. ...Read More
Frequently Asked Questions About Integra LifeSciences Holdings (IART) Stock
Based on ratings from 6 analysts Integra LifeSciences Holdings's stock is Under-perform. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, 8 sell and 3 hold ratings.
Unfortunately we do not have enough data on IART's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for IART is USD 24.50 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 16.
IART stock's Price/Earning ratio is 65.90.
Our analysis grades IART stock's Price / Earning ratio at F. This means that IART stock's Price/Earning ratio is above 71% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this IART may be a overvalued for its sector.
The last closing price of IART's stock was USD 22.88.
The most recent market capitalization for IART is USD 1.48B.
Based on targets from 6 analysts, the average taret price for IART is projected at USD 24.50 over the next 12 months.
This means that IART's stock price may go up by +7.08% over the next 12 months.
We can't find any ETFs which contains Integra LifeSciences Holdings's stock.
As per our most recent records Integra LifeSciences Holdings has 3,946 Employees.
Integra LifeSciences Holdings's registered address is 1100 Campus Road, Princeton, NJ, United States, 08540.
You can get more information about it from Integra LifeSciences Holdings's website at https://www.integralife.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Integra LifeSciences Holdings (IART) Stock
Based on ratings from 6 analysts Integra LifeSciences Holdings's stock is Under-perform. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, 8 sell and 3 hold ratings.
Unfortunately we do not have enough data on IART's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for IART is USD 24.50 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 16.
IART stock's Price/Earning ratio is 65.90.
Our analysis grades IART stock's Price / Earning ratio at F. This means that IART stock's Price/Earning ratio is above 71% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this IART may be a overvalued for its sector.
The last closing price of IART's stock was USD 22.88.
The most recent market capitalization for IART is USD 1.48B.
Based on targets from 6 analysts, the average taret price for IART is projected at USD 24.50 over the next 12 months.
This means that IART's stock price may go up by +7.08% over the next 12 months.
We can't find any ETFs which contains Integra LifeSciences Holdings's stock.
As per our most recent records Integra LifeSciences Holdings has 3,946 Employees.
Integra LifeSciences Holdings's registered address is 1100 Campus Road, Princeton, NJ, United States, 08540.
You can get more information about it from Integra LifeSciences Holdings's website at https://www.integralife.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IART !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
